NCT04211259RecruitingEarly phase 1
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 23 Dec 2019
- Start date
- 18 Apr 2022
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Rutgers, The State University of New Jersey
- Diseases
- Multiple myeloma
- NCT number
- NCT04211259
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 70
- From 18 Apr 2022 to the primary completion date, 31 Aug 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
- On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study
Other illness
- Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
- Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
Other
- Non-English speaking person
Who the study is looking for
- Patient must be able to provide informed consent
- Patients with confirmed diagnosis of multiple myeloma
- Able to swallow and retain oral medication
- All ethnic groups are eligible
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick Coordinator of this site? Confirm its status | New Brunswick | United States | Not yet recruiting |
| Rutgers Cancer Institute of New Jersey Coordinator of this site? Confirm its status | New Brunswick | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.